Funds will be used to advance pre-clinical and manufacturing development programmes and prepare for clinical studies. Leeds, UK, 13 May 2021: LUNAC Therapeutics (LUNAC), a UK-based drug discovery company focused on the development of advanced life-saving anticoagulants, announces it has raised £4.75 million in an…
Seven accepted abstracts, including an oral presentation, reinforce the potential of pegcetacoplan, an investigational, targeted C3 therapy, to redefine treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH) PDUFA action date of May 14, 2021 set by the U.S. Food and Drug Administration (FDA) WALTHAM, Mass.,…
Marketing application for pegcetacoplan for paroxysmal nocturnal hemoglobinuria (PNH) is under review by the U.S. Food and Drug Administration (FDA) with a PDUFA target action date of May 14, 2021 Top-line results from the Phase 3 PRINCE study in treatment-naïve PNH patients expected in the…
Post hoc analysis showed a 46% decrease in mean lesion growth in eight patients with bilateral GA comparing treated eye vs. untreated fellow eye at 24 months (p=0.007) Top-line data from Phase 3 DERBY and OAKS studies expected in Q3 2021 WALTHAM, Mass., April…
New UK company backed by Epidarex Capital emerges from stealth Cambridge, UK, March 23, 2021 – Dunad Therapeutics (“Dunad”) emerges today to develop next-generation small molecule therapeutics based on its highly differentiated, tuneable and targeted protein degradation technology. Dunad, secured initial financing from Epidarex Capital,…
Pegcetacoplan, an investigational targeted C3 therapy for serious, complement-driven diseases, demonstrated superiority to eculizumab with a statistically significant improvement in hemoglobin levels and showed improvements in key clinical outcomes Marketing applications for pegcetacoplan are under Priority Review with the FDA and under review with the…
Data published in Ophthalmology and the American Journal of Ophthalmology underscore the potential of pegcetacoplan, an investigational targeted C3 therapy, for geographic atrophy WALTHAM, Mass., March 10, 2021 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that two…
Leeds, UK, 5 February 2021: LUNAC Therapeutics (LUNAC), a UK based drug discovery company focused on the development of advanced life-saving anticoagulants, has been named as this year’s Start Up of the Year winner at the 19th Bionow Awards. The 19th Bionow Awards took place…
CHARLOTTESVILLE, Va. —Slate Bio, Inc., announced today the closing of a $1.75 million venture financing. Epidarex Capital led the investment round with participation from the UVA Licensing & Ventures Group Seed Fund, Center for Innovative Technology’s GAP BioLife Fund, VTC Seed Fund, PharmaDirections, Inc., management and others….
Oxford, UK, 7th January 2020 – Theolytics, a UK biotech harnessing viruses to combat cancer, today announced the closing of a US $7 million (UK £5 million) Series A round. The financing was co-led by Epidarex Capital and Taiho Ventures LLC with participation from existing…